| Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom … S Obeng, SH Kamble, ME Reeves, LF Restrepo, A Patel, M Behnke, ... Journal of medicinal chemistry 63 (1), 433-439, 2019 | 109 | 2019 |
| Pharmacological comparison of mitragynine and 7-hydroxymitragynine: in vitro affinity and efficacy for μ-opioid receptor and opioid-like behavioral effects in rats S Obeng, JL Wilkerson, F León, ME Reeves, LF Restrepo, ... Journal of Pharmacology and Experimental Therapeutics 376 (3), 410-427, 2021 | 64 | 2021 |
| Novel approaches, drug candidates, and targets in pain drug discovery S Obeng, T Hiranita, F León, LR McMahon, CR McCurdy Journal of medicinal chemistry 64 (10), 6523-6548, 2021 | 52 | 2021 |
| The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats T Hiranita, F Leon, JS Felix, LF Restrepo, ME Reeves, AE Pennington, ... Psychopharmacology 236, 2725-2734, 2019 | 47 | 2019 |
| Activity of Mitragyna speciosa (“Kratom”) Alkaloids at Serotonin Receptors F León, S Obeng, M Mottinelli, Y Chen, TI King, EC Berthold, SH Kamble, ... Journal of medicinal chemistry 64 (18), 13510-13523, 2021 | 45 | 2021 |
| Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats KL Schwienteck, KE Faunce, KC Rice, S Obeng, Y Zhang, BE Blough, ... Neuropharmacology 150, 200-209, 2019 | 42 | 2019 |
| Antinociceptive interactions between the imidazoline I2 receptor agonist 2-BFI and opioids in rats: role of efficacy at the μ-opioid receptor JN Siemian, S Obeng, Y Zhang, Y Zhang, JX Li Journal of Pharmacology and Experimental Therapeutics 357 (3), 509-519, 2016 | 34 | 2016 |
| Structure–activity relationship studies of 6α-and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the “message-address … S Obeng, H Wang, A Jali, DL Stevens, HI Akbarali, WL Dewey, DE Selley, ... ACS chemical neuroscience 10 (3), 1075-1090, 2018 | 30 | 2018 |
| Application of receptor theory to the design and use of fixed-proportion mu-opioid agonist and antagonist mixtures in rhesus monkeys JC Cornelissen, S Obeng, KC Rice, Y Zhang, SS Negus, ML Banks Journal of Pharmacology and Experimental Therapeutics 365 (1), 37-47, 2018 | 23 | 2018 |
| Design, synthesis, and biological evaluation of the third generation 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6β-[(4′-pyridyl) carboxamido] morphinan (NAP … Y Zheng, S Obeng, H Wang, AM Jali, B Peddibhotla, DA Williams, C Zou, ... Journal of medicinal chemistry 62 (2), 561-574, 2019 | 22 | 2019 |
| Anionic phospholipids control mechanisms of GPCR-G protein recognition N Thakur, AP Ray, L Sharp, B Jin, A Duong, NG Pour, S Obeng, ... Nature Communications 14 (1), 794, 2023 | 20 | 2023 |
| Characterization of 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6α-(indole-7-carboxamido) morphinan (NAN) as a novel opioid receptor modulator for opioid use disorder … S Obeng, A Jali, Y Zheng, H Wang, KL Schwienteck, C Chen, DL Stevens, ... ACS chemical neuroscience 10 (5), 2518-2532, 2019 | 19 | 2019 |
| Slow conformational dynamics of the human A2A adenosine receptor are temporally ordered S Wei, N Thakur, AP Ray, B Jin, S Obeng, CR McCurdy, LR McMahon, ... Structure 30 (3), 329-337. e5, 2022 | 18 | 2022 |
| In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6α-(isoquinoline-3-carboxamido) morphinan (NAQ) as a low efficacy … S Obeng, Y Yuan, A Jali, DE Selley, Y Zhang European journal of pharmacology 827, 32-40, 2018 | 16 | 2018 |
| Interactive effects of µ-opioid and adrenergic-α2 receptor agonists in rats: pharmacological investigation of the primary kratom alkaloid mitragynine and its metabolite 7 … S Obeng, F Leon, A Patel, JDZ Gonzalez, LC Da Silva, LF Restrepo, ... Journal of Pharmacology and Experimental Therapeutics 383 (3), 182-198, 2022 | 15 | 2022 |
| In vitro and in vivo pharmacology of kratom T Hiranita, S Obeng, A Sharma, JL Wilkerson, CR McCurdy, LR McMahon Advances in Pharmacology 93, 35-76, 2022 | 15 | 2022 |
| Application of bivalent bioisostere concept on design and discovery of potent opioid receptor modulators H Ma, S Obeng, H Wang, Y Zheng, M Li, AM Jali, DL Stevens, WL Dewey, ... Journal of Medicinal Chemistry 62 (24), 11399-11415, 2019 | 15 | 2019 |
| Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy JA Meade, Y Alkhlaif, KM Contreras, S Obeng, W Toma, LJ Sim-Selley, ... Psychopharmacology 237, 2777-2793, 2020 | 13 | 2020 |
| Potential Contribution of 7‐Hydroxymitragynine, a Metabolite of the Primary Kratom (Mitragyna Speciosa) Alkaloid Mitragynine, to the μ‐Opioid Activity of … T Hiranita, A Sharma, FL Oyola, S Obeng, ME Reeves, LF Restrepo, ... The FASEB journal 34 (S1), 1-1, 2020 | 9 | 2020 |
| The Adrenergic a2 Receptor‐Mediated Discriminative‐Stimulus Effects of Mitragynine, the Primary Alkaloid in Kratom (Mitragyna Speciosa) in Rats ME Reeve, S Obeng, FL Oyola, M Behnke, LF Restrepo, A Patel, NP Ho, ... The FASEB Journal 34 (S1), 1-1, 2020 | 9 | 2020 |
Jun-Xu LiProfessor, University at BuffaloVerified email at buffalo.edu
